Reviva Pharmaceuticals Holdings, Inc.

A US approval decision for Bristol Myers Squibb Company ’s schizophrenia candidate KarXT is approaching fast, and the impressive efficacy the muscarinic M1/ M4 agonist showed in Phase III means the v

Reviva Pharmaceuticals Holdings, Inc. saw its stock price jump nearly 50% on 30 October after the small-cap company reported that brilaroxazine succeeded in its first Phase III clinical trial in schi

Roche Pays $40m Up Front In Pact With Jnana Roche Holding AG agreed to pay $40m up front on 21 July under a partnership with Jnana Therapeutics Inc. centered on targeting solute carrier (SLC) prot

IN VITRO DIAGNOSTICS Asuragen Inc. Series D round brings $15mm to Asuragen Asuragen Inc. (mRNA- and miRNA-based molecular diagnostics for cancer and genetic diseases) raised $15mm from 15 undi